Analyst Sees Biogen and ImClone as Likely M&A Targets and To a Lesser Extent Genzyme
Tweet Send to a Friend
In a research note today from Citigroup, commenting on biotech M&A possibilities, the firm said Biogen (Nasdaq: BIIB) and ImClone ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
